Evotec AG and Harvard Stem Cell Institute Form CureMN Collaboration to Advance ALS Research

HAMBURG, Germany, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced a strategic partnership with the Harvard Stem Cell Institute ("HSCI") to identify compounds that prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis ("ALS"). The collaboration "CureMN" (CureMotorNeuron) will leverage human motor neuron assays based on ALS patient-derived induced pluripotent stem ("iPS") cells that were developed by Dr Lee Rubin, HSCI Principal Faculty member and professor in the Department of Stem Cell and Regenerative Biology at Harvard, and Dr Kevin Eggan, Early Career Scientist at the Howard Hughes Medical Institute, HSCI Principal Faculty member and professor in the Department of Stem Cell and Regenerative Biology at Harvard as well as Evotec's leading drug discovery infrastructure and expertise to identify compounds that will have therapeutic value against this life-threatening disease.

Help employers find you! Check out all the jobs and post your resume.